John E Moore
Overview
Explore the profile of John E Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
269
Citations
2246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millar B, Alexander L, Bell J, Grieve E, McCabe C, Wright E, et al.
Ulster Med J
. 2024 Dec;
93(2):67-82.
PMID: 39669952
Background: In Northern Ireland, approximately 550 people with cystic fibrosis (PwCF) attend the regional paediatric and adult centres within the Belfast Health and Social Care Trust. This autosomal recessive chronic...
2.
Moore J, Millar B
Sci One Health
. 2024 Dec;
3:100088.
PMID: 39633846
Background: The One Health approach involves collaboration across several sectors, including public health, veterinary and environmental sectors in an integrated manner. These sectors may be disparate and unrelated, however to...
3.
Shannon C, Millar B, Moore J
Br J Biomed Sci
. 2024 Nov;
81:13566.
PMID: 39502459
Background: Tuberculosis (TB) continues be the leading cause of death globally due to an infectious agent. There is a paucity of data describing the readability of patient-facing TB information for...
4.
Moore J, Millar B
Infect Med (Beijing)
. 2024 Sep;
3(3):100125.
PMID: 39314805
Background: People with cystic fibrosis (CF) may develop clinically significant chronic respiratory infections with (PA) and non-tuberculous mycobacteria (NTM). Open water has been suggested to be an important source for...
5.
Moore J, Millar B
Lung
. 2024 Jul;
202(5):741-751.
PMID: 39060416
Objectives: Readability of patient-facing information of oral antibiotics detailed in the WHO all oral short (6 months, 9 months) has not been described to date. The aim of this study...
6.
Moore J, McCaughan J, Rendall J, Millar B
Br J Biomed Sci
. 2024 Jun;
81:12749.
PMID: 38895586
Within cystic fibrosis microbiology, there is often mismatch between the antibiotic susceptibility result of an isolated bacterial pathogen and the clinical outcome, when the patient is treated with the same...
7.
Millar B, Bell J, Rendall J, Moore J
Physiotherapy
. 2024 Jun;
124():101-105.
PMID: 38875837
Objectives: To estimate the carriage of Neisseira meningitidis (meningococci) in expectorated sputum from people with cystic fibrosis (CF) and to evaluate potential ramifications of such carriage for the health and...
8.
Millar B, Rendall J, Moore J
Infect Dis Health
. 2024 Apr;
29(4):185-195.
PMID: 38644104
Background: Respiratory infection is a major cause of disease severity in people with cystic fibrosis (PwCF). This project aimed to establish the CF community's opinion regarding cross infection (CI), nebuliser...
9.
Moore J, Millar B
Clin Microbiol Infect
. 2024 Jan;
30(4):561-563.
PMID: 38272179
No abstract available.
10.
Moore J, Millar B
J Travel Med
. 2024 Jan;
PMID: 38206876
Readability of COVID-19 information from 35 cruise lines was examined. Mean Flesch Reading Ease and Flesch-Kincaid Grade Level scores (±standard error of mean) were 46.6 ± 1.3 (target ≥60) and...